Diffuse large B-cell lymphoma (DLBCL) is an heterogenous cancer that can have profound differences in survival outcomes. Molecular profiling has allowed for the identification of DLBCL subclasses, and together with clinical prognostic factors, such as the international prognostic index, have improved clinical care and survival. Despite these advances, a gene signature that is associated with overall survival (OS) and is reproducible across different DLBCL studies could better classify risk and predict OS. Here, we have identified genes that are associated with OS in DLBCL using data from the Lymphoma/Leukemia Molecular Profiling Project and developed a prognostic gene signature consisting of 33 genes that — when transformed into a risk score — can stratify individuals into high or low risk groups that have significantly different OS. The prognostic gene signature was associated with OS in multiple clinical studies, and when used in conjunction with DLBCL molecular subtype and IPI score, significantly predicted OS. Thus, we identified a potential prognostic gene signature that can discriminate high-risk from low-risk DLBCL patients.

弥漫性大B细胞淋巴瘤（DLBCL）是一种异源性癌症，其生存结局可能有很大差异。分子谱分析已经可以鉴定DLBCL的亚类，并且与临床预后因素（例如国际预后指数）一起改善了临床护理和生存率。尽管取得了这些进展，但与不同的总生存期（OS）相关联且可在不同DLBCL研究中重现的基因签名可以更好地对风险进行分类并预测OS。在这里，我们使用淋巴瘤/白血病分子分析项目的数据鉴定了与DLBCL中OS相关的基因，并开发了由33个基因组成的预后性基因签名-当转化为风险分数时，可以将个体分为高风险或低风险具有明显不同的操作系统的组。在多个临床研究中，预后基因签名与OS相关，并且当与DLBCL分子亚型和IPI分数结合使用时，可以显着预测OS。因此，我们确定了潜在的预后基因特征，可以区分高危和低危DLBCL患者。